Vanguards of Health Care by Bloomberg Intelligence
Vanguards of Health Care by Bloomberg Intelligence
Vanguards of Health Care is a series of exclusive conversations with management teams and thought leaders discussing changes on the forefront of the industry, including innovations in medical products and technologies, advances in clinical research, new service models, wellness and regulations.Social links:
Follow the podcast:
Transcarent’s Bet on AI and the End of Healthcare Scarcity
“Health care creates friction everywhere — copays, approvals, pre-authorizations — and none of that matters when someone you love needs help right now,” says Glen Tullman, CEO of Transcarent, in his return to the Vanguards of Health Care podcast to explain why speed, access and simplicity are exist…
49:54
Sofinnova Partners Stays Optimistic on Biotech's Future
Despite all the noise -- tariffs, regulation, geopolitics -- the fundamentals are amazing, because our companies save people’s lives and the demand for innovation is absolutely real.” says Antoine Papiernik, Sofinnova Partners Chairman and Managing Partner. Speaking with Bloomberg Intelligence anal…
57:52
Smarter Technologies’ Blueprint for AI-Driven Revenue Cycle Management
“Revenue cycle is really about solving two problems: generating an accurate receipt and then jumping through the fifty hoops to get paid.” says Dr. Michael Gao, CEO of Smarter Technologies. In this episode of Vanguards of Health Care, Gao joins Bloomberg Intelligence analyst Jonathan Palmer to expl…
52:37
Merck’s GHI Fund and the Push to Rewire Pharma's Future
“Our mission is to create both strategic and financial returns by backing scalable technologies that can transform how biopharma operates.” Bill Taranto, president and general partner of the Merck Global Health Innovation Fund, joins Bloomberg Intelligence analyst Jonathan Palmer to break down how …
52:25
Zymeworks on Rethinking Risk, Royalties and R&D
“We were a very valuable deep-science company that had the wrong business strategy,” Zymeworks CEO Ken Galbraith tells Bloomberg Intelligence analyst Sam Fazeli on this episode of the Vanguards of Health Care podcast. In discussing the company’s strategic reset, Galbraith explains how Zymeworks shi…
1:03:59
Penumbra Builds Clinical Support Showing Computer Assistance Can Better Address Clot
Vanguards of Health Care: Penumbra Expands CAVT Awareness “With pulmonary embolism, just like with stroke and some other things, where there’s an acute moment usually happening — the patient’s not doing well, decompressing on the table — time matters a lot. And because of the STORM-PE trial, we hav…
49:13Clean
Teva a Generic Giant With Biotech Bite
“Drug development has become slower and more expensive despite all the new technology,” says Eric Hughes, executive vice president of Global R&D and chief medical officer of Teva Pharmaceutical. “That’s caused by increased regulatory scrutiny, more needs for quality, more needs for real treatment e…
33:54
Aegis Ventures’ Blueprint for Building AI-Native Companies
“AI agents are at the knee of the curve in terms of where things are headed,” says John Beadle, Aegis Ventures co-founder and managing partner. In this episode of the Vanguards of Health Care podcast, Beadle joins Bloomberg Intelligence analyst Jonathan Palmer to unpack Aegis’s thesis-driven approa…
48:07
Beta Bionics Does the Work to Reduce Insulin Pump Burden
“In the case of iLet, we're going to say, this is how much insulin they're getting for what they consider to be a usual meal. And we learn that and we can set it that way. So we just take the responsibility of learning carb counting, which is really tough, off the user's plate. That's an extra leve…
40:33
Fosun Pharma’s Drive Beyond China
“If you’re not going overseas, you’re going out,” says Dr. Xingli Wang, Co-President of Fosun Pharma. He tells Bloomberg Intelligence’s Sam Fazeli how Fosun is transitioning from generics to novel medicines and positioning itself as a global innovator. With 90% of R&D now focused on oncology, autoi…
49:30